Molecular Partners among the best newcomers at European stock exchanges10.12.2015 09:13
Molecular Partners AG announced today that the company has achieved a top 3 ranking in the category “Most Innovative Newcomer” at the European Small and Mid-Cap Awards 2015 in Brussels. This annual awards ceremony recognizes the best European small and mid-sized companies who have gained access to capital markets via an Initial Public Offering.
Organized by the European Commission's Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs, in cooperation with European Issuers and the Federation of European Securities Exchanges (FESE), the European Small and Mid-Cap Awards promote best practices and success stories of the most dynamic companies listed on the European public capital markets. The awards were launched in 2013 with the aim of encouraging companies to access Europe’s capital markets.
“We are very proud about the award we received and we thank our shareholders for their ongoing trust and support,” said Christian Zahnd, Chief Executive Officer of Molecular Partners. “International capital markets have generously provided Molecular Partners with the resources necessary to advance our innovative DARPin technology and our pipeline of novel therapeutics for the treatment of serious diseases. Our private and public investors and the SIX Swiss Exchange have been truly supportive partners to our company in the year since we have been public and we are honored to share this award with you.”
Christoph Landis, Division CEO of SIX Swiss Exchange, commented: “We would like to congratulate Molecular Partners, a company listed on SIX Swiss Exchange, for their performance in finishing in the top 3 companies. As the leading stock exchange in Europe for the life science segment, we are delighted to have been able to provide advisory to Molecular Partners during their IPO and as they now enjoy the success of being public. We wish them all the very best for the future.”